OBJECTIVE: Methylmalonic acidemia (MMA) is a metabolic disorder with a poorly defined long-term neurocognitive phenotype. We studied the neuropsychological outcomes of patients and examined clinical covariates that influenced cognition. METHODS: A diverse cohort with mut, cblA, or cblB subtypes of isolated MMA (N = 43), ages 2 to 32 years, were evaluated at a single center over a 6-year period. The influence of clinical, laboratory, and metabolic parameters on neuropsychological testing results was determined. RESULTS: Early-onset mut patients (n = 21) manifested the most severe neurocognitive impairments, with a mean ± SD full-scale IQ (FSIQ) of 71.1 ± 14.75. Late-onset mut patients (n = 6) had a mean FSIQ of 88.5 ± 27.62. cblA (n = 7), cblB (n = 6), and mut patients diagnosed prenatally or by newborn screening (n = 3) obtained mean FSIQs in the average range (100.7 ± 10.95, 96.6 ± 10.92, and 106.7 ± 6.66, respectively). Hyperammonemia at diagnosis and the presence of a seizure disorder were associated with a lower FSIQ (P = .001 and P = .041, respectively), but other clinical variables, including basal ganglia injury and mutation status, did not. FSIQ remained stable over longitudinal testing (n = 10). Decreased scores on processing speed, compared with all other intellectual domains, emerged as a specific neurocognitive manifestation. CONCLUSIONS: The neurocognitive outcomes seen in isolated MMA are highly variable. An earlier age of disease onset, the presence of hyperammonemia at diagnosis, and a history of seizures were associated with more severe impairment. In all patient subtypes, selective deficits in processing speed were present.
OBJECTIVE:Methylmalonic acidemia (MMA) is a metabolic disorder with a poorly defined long-term neurocognitive phenotype. We studied the neuropsychological outcomes of patients and examined clinical covariates that influenced cognition. METHODS: A diverse cohort with mut, cblA, or cblB subtypes of isolated MMA (N = 43), ages 2 to 32 years, were evaluated at a single center over a 6-year period. The influence of clinical, laboratory, and metabolic parameters on neuropsychological testing results was determined. RESULTS: Early-onset mut patients (n = 21) manifested the most severe neurocognitive impairments, with a mean ± SD full-scale IQ (FSIQ) of 71.1 ± 14.75. Late-onset mut patients (n = 6) had a mean FSIQ of 88.5 ± 27.62. cblA (n = 7), cblB (n = 6), and mut patients diagnosed prenatally or by newborn screening (n = 3) obtained mean FSIQs in the average range (100.7 ± 10.95, 96.6 ± 10.92, and 106.7 ± 6.66, respectively). Hyperammonemia at diagnosis and the presence of a seizure disorder were associated with a lower FSIQ (P = .001 and P = .041, respectively), but other clinical variables, including basal ganglia injury and mutation status, did not. FSIQ remained stable over longitudinal testing (n = 10). Decreased scores on processing speed, compared with all other intellectual domains, emerged as a specific neurocognitive manifestation. CONCLUSIONS: The neurocognitive outcomes seen in isolated MMA are highly variable. An earlier age of disease onset, the presence of hyperammonemia at diagnosis, and a history of seizures were associated with more severe impairment. In all patient subtypes, selective deficits in processing speed were present.
Authors: S B van der Meer; F Poggi; M Spada; J P Bonnefont; H Ogier; P Hubert; E Depondt; D Rapoport; D Rabier; C Charpentier Journal: J Pediatr Date: 1994-12 Impact factor: 4.406
Authors: F Hörster; S F Garbade; T Zwickler; H I Aydin; O A Bodamer; A B Burlina; A M Das; J B C De Klerk; C Dionisi-Vici; S Geb; G Gökcay; N Guffon; E M Maier; E Morava; J H Walter; B Schwahn; F A Wijburg; M Lindner; S Grünewald; M R Baumgartner; S Kölker Journal: J Inherit Metab Dis Date: 2009-07-31 Impact factor: 4.982
Authors: Yiouli P Ktena; Trygg Ramstad; Eva H Baker; Jennifer L Sloan; Andrew J Mannes; Irini Manoli; Charles P Venditti Journal: J Inherit Metab Dis Date: 2015-05-19 Impact factor: 4.982
Authors: Renata T Costa; Marcella B Santos; Carlos Alberto-Silva; Daniel C Carrettiero; César A J Ribeiro Journal: Cell Mol Neurobiol Date: 2022-06-08 Impact factor: 5.046
Authors: E H Baker; J L Sloan; N S Hauser; A L Gropman; D R Adams; C Toro; I Manoli; C P Venditti Journal: AJNR Am J Neuroradiol Date: 2014-09-04 Impact factor: 3.825
Authors: Yiouli P Ktena; Scott M Paul; Natalie S Hauser; Jennifer L Sloan; Andrea Gropman; Irini Manoli; Charles P Venditti Journal: Am J Med Genet A Date: 2015-05-10 Impact factor: 2.578